A mouse study showing the same chemistry can be steered by a tumour-seeking protein instead of an injection, and can switch on MMAE, a toxin too harsh to give on its own.
Shasqi extends its platform in two directions. The drug is monomethyl auristatin E (MMAE), modified with a trans-cyclooctene to form the prodrug SQP22, which reduced its cytotoxicity in cells and in animals. The activator is either the tetrazine-modified hyaluronate SQL70 injected into the tumour, or SQT01, a tetrazine-modified HER2-targeting antigen-binding fragment given by infusion.
SQP22 with SQL70 had anti-tumour effects in the Karpas 299 and RENCA mouse models and showed that the click reaction was required for activation. SQP22 with SQT01 had anti-tumour effects in the HER2-positive NCI-N87 xenograft, showing that activation at the tumour could be achieved with both components given systemically. Toxicity was limited to transient myelosuppression and moderate loss of body weight.
It is the published basis for the antigen-targeted programmes on Shasqi's pipeline, which no longer need a tumour that can be injected. None of these has been tested in people.
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Click-activated prodrugs (bioorthogonal drug activation in the body), HER2.
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/